Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Economic information and modeling report

Modeling overview

20 evidence topics · 16 sources

Summary

  • Barzolvolimab has no published price and no budget impact model; a BLA submission is anticipated in 2027.
  • Comparator prices: remibrutinib $4,521 per 30-day supply (60 tablets) as of January 7, 2026; dupilumab $4,193.03 per 4-week supply as of January 1, 2026; omalizumab approximately $30,000 - $60,000 annually at list price (WAC) per Genentech and approximately $1472.76 per unit at the end of 2025 per the Oregon PDAB review. The Oregon PDAB review lists 2025 WACs per 30-day supply of $5,891 for omalizumab 600 mg every 1 month and $3,993 for dupilumab 300 mg every 2 weeks.
  • Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
  • Published cost-effectiveness analyses of comparators report ICERs for omalizumab of £27,469 per QALY gained (NICE TA339, with the patient access scheme), £3183 (UK societal, Novartis-funded), €17 502 per QALY gained (Netherlands societal), and ¥160,411/QALY (China, patient perspective); a US poster reports $3,208,966 per QALY over 10 years for remibrutinib with cetirizine. NICE draft guidance of September 2026 states that remibrutinib should not be used for CSU inadequately controlled by H1-antihistamines in adults. No dupilumab cost-effectiveness analysis in CSU was found.
  • The UK omalizumab model assigns utilities from 0.712 for UAS7 = 28–42 to 0.897 for UAS7 = 0.
  • Celldex states a prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States.

Wholesale acquisition cost per 30-day supply of omalizumab and dupilumab in 2025

ProductQuoted dosage and frequencyQuoted yearQuoted WAC per 30-day supply
Omalizumab (Xolair)“600 mg every 1 month”“2025”“$5,891”
Dupilumab (Dupixent)“300 mg every 2 weeks”“2025”“$3,993”

Dupilumab cost-effectiveness analysis in CSU

No evidence found.